{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:58:07Z","timestamp":1781801887789,"version":"3.54.5"},"reference-count":39,"publisher":"American Diabetes Association","issue":"5","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"name":"German Diabetes Association"},{"DOI":"10.13039\/100010781","name":"German Diabetes Foundation","doi-asserted-by":"crossref","award":["FP-0438-2021"],"award-info":[{"award-number":["FP-0438-2021"]}],"id":[{"id":"10.13039\/100010781","id-type":"DOI","asserted-by":"crossref"}]},{"name":"German Robert Koch Institute"},{"name":"German Federal Ministry for Education and Research within the German Center for Diabetes Research","award":["82DZD14E03 and 82DZD14E1G"],"award-info":[{"award-number":["82DZD14E03 and 82DZD14E1G"]}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>We investigated the prevalence of elevated LDL cholesterol in youth with type 1 diabetes (T1D), contributing factors, the frequency of lipid-lowering medication (LLM), and the achievement of target values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>A cross-sectional analysis based on data from the Diabetes-Patienten-Verlaufsdokumentation registry (Diabetes Prospective Follow-up Registry) from 2013 to 2023. Inclusion criteria were T1D, age &amp;lt;18 years, and at least one documented LDL measurement. LDL cutoffs of &amp;gt;2.6, &amp;gt;3.4, and &amp;gt;4.1 mmol\/L were defined. Application of national and international treatment guidelines was examined. Descriptive analyses and linear and logistic regression models were implemented using SAS 9.4.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>The study included 55,028 participants. Of these, 9.7% and 2.3% had LDL &amp;gt;3.4 mmol\/L and &amp;gt;4.1 mmol\/L, respectively. The parameters HbA1c (\u03b2 = 1,142.7; P = 0.001), female sex (\u03b2 = 861.5; P &amp;lt; 0.001), and BMI \u2009&amp;gt;70th percentile (\u03b2 = 520.1; P &amp;lt; 0.001) had the strongest effect on LDL levels. Only 7.3% of the cohort with elevated LDL levels received LLM. The majority (92.7%) with LDL &amp;gt;3.4 mmol\/L and 87.0% with LDL &amp;gt;4.1 mmol\/L were not treated. Estimated odds ratios (95% CI) for the use of LLM were 19.13 (15.4\u201323.7) for LDL &amp;gt;4.1 mmol\/L; 3.1 (1.82\u20135.41) for ages 12\u201318 years; 2.31 (1.9\u20132.1) for diabetes duration of 5\u201310 years; 1.8 (1.5\u20132.1) for BMI \u2009&amp;gt;70th percentile; 1.3 (1.0\u20131.6) for HbA1c &amp;gt;9%; and 1.18 (1.0\u20131.4) for female sex. However, only 15.7% of the treated patients (n = 707) reached the LDL target of &amp;lt;2.6 mmol\/L, and LDL levels of 55% even remained at &amp;gt;3.4 mmol\/L.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>We found a high prevalence of LDL hypercholesterolemia. The use of LLM was low, despite treatment indication, and treatment targets were mostly not achieved either due to underdosing or nonadherence to LLM. These findings confirm that dyslipidemia remains an underestimated cardiovascular risk factor in pediatric diabetology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc25-2459","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:40:34Z","timestamp":1773758434000},"page":"755-762","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":0,"title":["Hypercholesterolemia and Lipid-Lowering Therapy in Children and Adolescents With Type 1 Diabetes: Do We Implement Current Guidelines?"],"prefix":"10.2337","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8663-3723","authenticated-orcid":false,"given":"Jantje","family":"Weiskorn","sequence":"first","affiliation":[{"name":"Department for Diabetology, Endocrinology and Clinical Research, AUF DER BULT, Children\u2019s Hospital 1 , Hanover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1643-1935","authenticated-orcid":false,"given":"Marianne","family":"Becker","sequence":"additional","affiliation":[{"name":"Department for Pediatric Endocrinology and Diabetology, Centre Hospitalier de Luxembourg 2 , Luxembourg, Luxembourg"},{"name":"Research Group on Growth and Development, Vrije Universiteit Brussel University 3 , Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8241-4105","authenticated-orcid":false,"given":"Clemens","family":"Kamrath","sequence":"additional","affiliation":[{"name":"University Children\u2019s Hospital 4 , Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8821-5775","authenticated-orcid":false,"given":"Johanna","family":"Hammersen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University Hospital Erlangen 5 , Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Bechtold-Dalla Pozza","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-University Munich 6 , Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"M\u00fcller-Ro\u00dfberg","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology and Diabetes, Children\u2019s Hospital 7 , Esslingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6577-5400","authenticated-orcid":false,"given":"Martin","family":"Holder","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology and Diabetology, Klinikum Stuttgart, Olgahospital 8 , Stuttgart, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6274-5900","authenticated-orcid":false,"given":"Marie-Anne","family":"Burckhardt","sequence":"additional","affiliation":[{"name":"Pediatric Endocrinology and Diabetology, University Children\u2019s Hospital Basel and Department of Clinical Research, University of Basel 9 , Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard Walter","family":"Holl","sequence":"additional","affiliation":[{"name":"German Center for Diabetes Research 10 , M\u00fcnchen-Neuherberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"2026061812463204800_B1","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1161\/CIRCULATIONAHA.118.037454","article-title":"Relative prognostic importance and optimal levels of risk factors for mortality and cardiovascular outcomes in type 1 diabetes mellitus","volume":"139","author":"Rawshani","year":"2019","journal-title":"Circulation"},{"key":"2026061812463204800_B2","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s00125-005-0120-4","article-title":"All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK General Practice Research Database, 1992\u20131999","volume":"49","author":"Soedamah-Muthu","year":"2006","journal-title":"Diabetologia"},{"key":"2026061812463204800_B3","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa1408214","article-title":"Glycemic control and excess mortality in type 1 diabetes","volume":"371","author":"Lind","year":"2014","journal-title":"N Engl J Med"},{"key":"2026061812463204800_B4","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1161\/CIR.0000000000000618","article-title":"Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association","volume":"139","author":"de Ferranti","year":"2019","journal-title":"Circulation"},{"key":"2026061812463204800_B5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4274\/Jcrpe.893","article-title":"Diabetes care, glycemic control, complications, and concomitant autoimmune diseases in children with type 1 diabetes in Turkey: a multicenter study","volume":"5","author":"Simsek","year":"2013","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"2026061812463204800_B6","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2337\/diacare.28.5.1051","article-title":"Awareness and treatment of dyslipidemia in young adults with type 1 diabetes","volume":"28","author":"Wadwa","year":"2005","journal-title":"Diabetes Care"},{"key":"2026061812463204800_B7","first-page":"130","article-title":"Dyslipidaemia in recently diagnosed young subjects of type 1 diabetes mellitus with normal\/favourable BMI: a risk factor of macrovascular disease","volume":"24","author":"Hamad","year":"2008","journal-title":"Biomedica"},{"key":"2026061812463204800_B8","doi-asserted-by":"crossref","first-page":"e000625","DOI":"10.1136\/bmjdrc-2018-000625","article-title":"Cardiovascular risk factors from diagnosis in children with type 1 diabetes mellitus: a longitudinal cohort study","volume":"7","author":"Jones","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2026061812463204800_B9","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.2337\/dc10-0505","article-title":"Early signs of atherosclerosis in diabetic children on intensive insulin treatment: a population-based study","volume":"33","author":"Margeirsdottir","year":"2010","journal-title":"Diabetes Care"},{"key":"2026061812463204800_B10","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1399-5448.2010.00665.x","article-title":"Characterization of 33 488 children and adolescents with type 1 diabetes based on the gender-specific increase of cardiovascular risk factors","volume":"11","author":"Schwab","year":"2010","journal-title":"Pediatr Diabetes"},{"key":"2026061812463204800_B11","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jpeds.2004.06.042","article-title":"Early onset of subclinical atherosclerosis in young persons with type 1 diabetes","volume":"145","author":"Krantz","year":"2004","journal-title":"J Pediatr"},{"key":"2026061812463204800_B12","doi-asserted-by":"crossref","first-page":"3L","DOI":"10.1016\/S0002-9149(02)02953-3","article-title":"Childhood risk factors predict adult risk associated with subclinical cardiovascular disease. The Bogalusa Heart Study","volume":"90","author":"Berenson","year":"2002","journal-title":"Am J Cardiol"},{"key":"2026061812463204800_B13","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1056\/NEJM199806043382302","article-title":"Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study","volume":"338","author":"Berenson","year":"1998","journal-title":"N Engl J Med"},{"key":"2026061812463204800_B14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1515\/jpem-2016-0111","article-title":"The prevalence of dyslipidemia and associated factors in children and adolescents with type 1 diabetes","volume":"30","author":"Bulut","year":"2017","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2026061812463204800_B15","first-page":"256","article-title":"Jeremiah Metzger Lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL?","volume":"122","author":"Gotto","year":"2011","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"2026061812463204800_B16","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1161\/CIRCULATIONAHA.107.181946","article-title":"Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing","volume":"115","author":"McCrindle","year":"2007","journal-title":"Circulation"},{"key":"2026061812463204800_B17","doi-asserted-by":"crossref","first-page":"S258","DOI":"10.2337\/dc24-S014","article-title":"14. Children and adolescents: Standards of Care in Diabetes\u20142024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2023","journal-title":"Diabetes Care"},{"key":"2026061812463204800_B18","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/pedi.13444","article-title":"ISPAD Clinical Practice Consensus Guidelines 2022: microvascular and macrovascular complications in children and adolescents with diabetes","volume":"23","author":"Bjornstad","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"2026061812463204800_B19","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/1471-2458-8-196","article-title":"The challenge of comprehensively mapping children\u2019s health in a nation-wide health survey: design of the German KiGGS-Study","volume":"8","author":"Kurth","year":"2008","journal-title":"BMC Public Health"},{"key":"2026061812463204800_B20","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/dme.13963","article-title":"Lipid profile is associated with treatment regimen in a large cohort of children and adolescents with type 1 diabetes mellitus: a study from the international SWEET database","volume":"36","author":"Kosteria","year":"2019","journal-title":"Diabet Med"},{"key":"2026061812463204800_B21","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2337\/diacare.29.02.06.dc05-0724","article-title":"Spectrum and prevalence of atherogenic risk factors in 27,358 children, adolescents, and young adults with type 1 diabetes: cross-sectional data from the German diabetes documentation and quality management system (DPV)","volume":"29","author":"Schwab","year":"2006","journal-title":"Diabetes Care"},{"key":"2026061812463204800_B22","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2337\/dc08-1641","article-title":"Prevalence of abnormal lipid profiles and the relationship with the development of microalbuminuria in adolescents with type 1 diabetes","volume":"32","author":"Loredana Marcovecchio","year":"2009","journal-title":"Diabetes Care"},{"key":"2026061812463204800_B23","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jpeds.2006.10.054","article-title":"Longitudinal lipid screening and use of lipid-lowering medications in pediatric type 1 diabetes","volume":"150","author":"Maahs","year":"2007","journal-title":"J Pediatr"},{"key":"2026061812463204800_B24","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jacl.2013.12.006","article-title":"Non-HDL-cholesterol in an adolescent diabetes population","volume":"8","author":"Kuryan","year":"2014","journal-title":"J Clin Lipidol"},{"key":"2026061812463204800_B25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1399-5448.2010.00733.x","article-title":"A longitudinal assessment of lipids in youth with type 1 diabetes","volume":"12","author":"Southern Reh","year":"2011","journal-title":"Pediatric Diabetes"},{"key":"2026061812463204800_B26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jpeds.2012.06.006","article-title":"Glucose control predicts 2-year change in lipid profile in youth with type 1 diabetes","volume":"162","author":"Maahs","year":"2013","journal-title":"J Pediatr"},{"key":"2026061812463204800_B27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2337\/dc16-0430","article-title":"Influence of HbA1c and BMI on lipid trajectories in youths and young adults with type 1 diabetes","volume":"40","author":"Katz","year":"2017","journal-title":"Diabetes Care"},{"key":"2026061812463204800_B28","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/j.1464-5491.2008.02518.x","article-title":"Longitudinal screening of serum lipids in children and adolescents with type 1 diabetes in a UK clinic population","volume":"25","author":"Edge","year":"2008","journal-title":"Diabet Med"},{"key":"2026061812463204800_B29","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1186\/s12889-019-7901-z","article-title":"Age, maturation and serum lipid parameters: findings from the German Health Survey for Children and Adolescents","volume":"19","author":"Schienkiewitz","year":"2019","journal-title":"BMC Public Health"},{"key":"2026061812463204800_B30","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1001\/archinte.160.18.2756","article-title":"Prevalence and phenotypic distribution of dyslipidemia in type 1 diabetes mellitus: effect of glycemic control","volume":"160","author":"P\u00e9rez","year":"2000","journal-title":"Arch Intern Med"},{"key":"2026061812463204800_B31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1590\/2359-3997000000040","article-title":"Dyslipidemia in young patients with type 1 diabetes mellitus","volume":"59","author":"Homma","year":"2015","journal-title":"Arch Endocrinol Metab"},{"key":"2026061812463204800_B32","doi-asserted-by":"crossref","first-page":"117270","DOI":"10.1016\/j.atherosclerosis.2023.117270","article-title":"Sex differences in lipids: a life course approach","volume":"384","author":"Holven","year":"2023","journal-title":"Atherosclerosis"},{"key":"2026061812463204800_B33","unstructured":"Dortschy\n              R\n            , Rosario AS, Scheidt-Nave C, , Bev\u00f6lkerungsbezogene Verteilungswerte ausgew\u00e4hlter Laborparameter aus der Studie zur Gesundheit von Kindern und Jugendlichen in Deutschland (KiGGS).Berlin, Robert Koch-Institut,2009, p. 135"},{"key":"2026061812463204800_B34","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.eprac.2022.10.003","article-title":"Racial and ethnic cardiometabolic risk disparities in the Type 1 Diabetes Exchange Clinic Registry Cohort","volume":"28","author":"Griggs","year":"2022","journal-title":"Endocr Pract"},{"key":"2026061812463204800_B35","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.3390\/ijerph17113926","article-title":"Gender differences in medication use: a drug utilization study based on real world data","volume":"17","author":"Orlando","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"2026061812463204800_B36","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3390\/ijms24021366","article-title":"Statins in children, an update","volume":"24","author":"Fiorentino","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026061812463204800_B37","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1475-2840-10-53","article-title":"The effect of cardiovascular risk factors on the longitudinal evolution of the carotid intima medial thickness in children with type 1 diabetes mellitus","volume":"10","author":"Dalla Pozza","year":"2011","journal-title":"Cardiovasc Diabetol"},{"key":"2026061812463204800_B38","doi-asserted-by":"crossref","first-page":"100177","DOI":"10.1016\/j.ajpc.2021.100177","article-title":"Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC\/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States","volume":"6","author":"Baum","year":"2021","journal-title":"Am J Prev Cardiol"},{"key":"2026061812463204800_B39","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.2337\/dc18-0724","article-title":"Area deprivation and regional disparities in treatment and outcome quality of 29,284 pediatric patients with type 1 diabetes in germany: a cross-sectional multicenter DPV Analysis","volume":"41","author":"Auzanneau","year":"2018","journal-title":"Diabetes Care"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/49\/5\/755\/859532\/dc252459.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/49\/5\/755\/859532\/dc252459.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:46:42Z","timestamp":1781801202000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/49\/5\/755\/164610\/Hypercholesterolemia-and-Lipid-Lowering-Therapy-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3,17]]},"published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc25-2459","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]}}}